Anaplastic large cell lymphoma (ALCL) is an uncommon, aggressive form of non-Hodgkin lymphoma caused due to CD30 antigen on tumor cells. There are two principal forms, that is primary cutaneous, which is typically limited to the skin and less aggressive, and systemic, which affects several organs and is frequently severe. Both ALK-positive and ALK-negative ALCL are possible. Younger individuals are more likely to have ALK-positive ALCL, which responds better to treatment. The anaplastic large cell lymphoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the anaplastic large cell lymphoma pipeline analysis include Pfizer, Hoffmann-La Roche, and Tessa Therapeutics, among others.
Leading drugs currently in the pipeline include Crizotinib, and Alectnib, others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Anaplastic Large Cell Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into anaplastic large cell lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for anaplastic large cell lymphoma. The anaplastic large cell lymphoma report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The anaplastic large cell lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with anaplastic large cell lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to anaplastic large cell lymphoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Anaplastic large cell lymphoma (ALCL) is typified by the unchecked growth of cancerous lymphocytes, frequently brought on by oncogenic translocations of the ALK gene. The resultant ALK fusion proteins promote cell growth, survival, and metabolic reprogramming by constitutively activating tyrosine kinase signaling pathways, particularly JAK/STAT, PI3K/AKT, and MAPK. By promoting proliferation, preventing apoptosis, and changing metabolism, these molecular alterations promote lymphomagenesis and result in aggressive tumor behavior.
Anaplastic large cell lymphoma (ALCL) treatment is contingent upon the disease's size and subtype. Anthracycline-based chemotherapy regimens such as CHOP or CHOEP are commonly used to treat systemic ALCL; ALK-positive cases respond better than ALK-negative ones. A targeted treatment called benuximab vedotin is frequently added or changed. For high-risk or relapsing cases, stem cell transplantation is taken into consideration. Surgical excision or localized radiation therapy are the standard treatments for primary cutaneous ALCL, while systemic therapy is used to treat extensive illness.
About 3–5% of all non-Hodgkin lymphomas and 10%–20% of juvenile lymphomas are anaplastic large cell lymphoma (ALCL), an uncommon form of non-Hodgkin lymphoma. It accounts for around 15% of peripheral T-cell lymphomas globally. In the United States, the incidence is approximately 0.25 cases per 100,000 persons per year. Even less common is breast implant-associated ALCL, whose incidence estimates vary greatly according on the type of implant and length of exposure.
This section of the report covers the analysis of anaplastic large cell lymphoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the anaplastic large cell lymphoma pipeline, maximum number of candidates lie in Phase II with 44%, followed by Phase I with 33%, while the remaining are divided equally in Phase III and IV. Thus, demonstrating a concentrated focus toward potential treatments.
The drug molecule categories covered under the anaplastic large cell lymphoma pipeline analysis include antibodies, antisense oligonucleotides, immunotherapies, monoclonal antibodies, peptides, proteins, recombinant proteins, small molecule, stem cells and vaccines. The anaplastic large cell lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for anaplastic large cell lymphoma.
The EMR report for the anaplastic large cell lymphoma pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in anaplastic large cell lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for anaplastic large cell lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of anaplastic large cell lymphoma drug candidates.
Crizotinib, developed by Pfizer, is an oral ALK inhibitor approved for pediatric and young adult patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL). It showed an 88% overall response rate with 81% complete remission. Currently, it is being studied in a Phase IV clinical trial to further assess its long-term safety and efficacy. Common side effects include vision issues, gastrointestinal disturbances, and fatigue.
Hoffmann-La Roche's Alectinib is a second-generation ALK inhibitor that has been authorized for use in treating non-small cell lung cancer (NSCLC) that is ALK-positive. For patients with resected Stage IB–IIIA ALK-positive NSCLC, it is presently being assessed as adjuvant therapy in the Phase III ALINA study. Compared to chemotherapy, alexinib showed a 76% lower risk of illness recurrence or death in this trial, along with a good safety record.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Anaplastic Large Cell Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for anaplastic large cell lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into anaplastic large cell lymphoma collaborations, regulatory environments, and potential growth opportunities.
Anaplastic Thyroid Cancer Drugs Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share